country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181915

Copy Link Print Information

PB2-IN-3

PB2-IN-3 (Compound 11) is a PB2 inhibitor. PB2-IN-3 exhibits antiviral activity against Influenza A H1N1 and H3N2 strains. PB2-IN-3 can be used in studies related to influenza A virus infection.

For research use only. We do not sell to patients.

Formula: C₂₆H₂₉F₂N₇O₃
Molecular Weight:525.55

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PB2-IN-3 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

PB2-IN-3 exhibits antiviral activity against the Influenza A H3N2 strain in MDCK cells, with an IC₅₀ of 0.011 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

Molecular Weight 525.55
Formula C₂₆H₂₉F₂N₇O₃
SMILES

O=C([C@@H]1CN(C(N[C@H]2C(CC3)CCC3[C@@H]2NC4=NC(C5=CNC6=NC=C(F)C=C65)=NC=C4F)=O)CCC1)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Hu Q, et al. Design, Synthesis, Molecular Dynamics Simulations, and Biological Evaluation of PB2 Inhibitors as Anti-Influenza A Virus Agent. ACS Med Chem Lett. 2026 Mar 2;17(3):688-694. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote